Drug Information

Drug (ID: DG01680) and It's Reported Resistant Information

• Name: AEB071/Binimetinib
• Synonyms: AEB071/Binimetinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Uveal melanoma [ICD-11: 2D0Y]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Guanine nucleotide-binding protein subunit alpha-11 (GNA11) [1]

• Molecule Alteration: Missense mutation; p.Q209L (c.626A>T)
• Sensitive Disease: Uveal melanoma [ICD-11: 2D0Y.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: OMM-GN11; N.A.; Mus musculus (Mouse); N.A.
• In Vitro Model: OMM13; N.A.; .; N.A.
• In Vitro Model: Mel202; Eye; Homo sapiens (Human); CVCL_C301
• In Vitro Model: GNAQ cells; N.A.; .; N.A.
• In Vitro Model: Mel270 cells; Skin; Homo sapiens (Human); CVCL_C302
• In Vitro Model: GNA11 cells; N.A.; .; N.A.
• In Vitro Model: UPMD-1 cells; Skin; Homo sapiens (Human); CVCL_C297
• In Vitro Model: 92-1 cells; Bladder; Homo sapiens (Human); CVCL_W909
• In Vitro Model: Mel202; Eye; Homo sapiens (Human); CVCL_C301
• In Vivo Model: C57/BL6 mouse model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Cell proliferation assay

References

• Ref 1: Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutationsOncogene. 2014 Sep 25;33(39):4724-34. doi: 10.1038/onc.2013.418. Epub 2013 Oct 21.